Clindamycin

Overview

Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic . Clindamycin can inhibit bacterial protein synthesis , possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.

Application

Products | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Bacterial Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > Parasite

Product Information

• Catalog No.: HY-B1455
• CAS No.: 18323-44-9
• Molecular Formula: C18H33ClN2O5S
• Molecular Weight: 424.98
• Purity: 99.90%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source